Literature DB >> 22430948

The aging patient with hemophilia.

Barbara A Konkle1.   

Abstract

The prospects for many boys born with hemophilia today include a normal life expectancy and minimal to no joint disease. However, despite the availability of safe replacement clotting factor concentrates and effective antiviral treatment, the aging patient with hemophilia today faces many challenges. These include management of their hemophilia as well as the same age-related health issues as experienced in the general population. While increasing, data on the prevalence of comorbidities and their management in the hemophilia population remain limited. This review will focus on issues related to management of hemophilia and complications of cardiovascular, musculoskeletal, hepatic, and renal disease. Available research is summarized and potential approaches to management are discussed.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22430948     DOI: 10.1002/ajh.23161

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  3 in total

1.  The social burden and quality of life of patients with haemophilia in Italy.

Authors:  Yllka Kodra; Marianna Cavazza; Arrigo Schieppati; Marta De Santis; Patrizio Armeni; Romano Arcieri; Gabriele Calizzani; Giovanni Fattore; Lamberto Manzoli; Lorenzo Mantovani; Domenica Taruscio
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

2.  Effects of short-term aerobic, resistance and combined exercises on the lipid profiles and quality of life in overweight individuals with moderate hemophilia A: A randomized controlled trial.

Authors:  Behrouz Parhampour; Mehdi Dadgoo; Giti Torkaman; Roya Ravanbod; Tina Delsouz Bahri; Mohammad Jazebi; Seyed Mehdi Mohsenipour; Behnoosh Vasaghi-Gharamaleki
Journal:  Med J Islam Repub Iran       Date:  2021-06-01

3.  BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years.

Authors:  Johnny Mahlangu; Maria Fernanda Lopez Fernandez; Elena Santagostino; Shadan Lalezari; Despina Tseneklidou-Stoeter; Horst Beckmann; Nikki Church
Journal:  Eur J Haematol       Date:  2020-03-23       Impact factor: 2.997

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.